Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

Rhea-AI Summary

Elutia (Nasdaq: ELUT) has received dual honors at the 2025 Medical Device Network Excellence Awards for Innovation and Product Launches, recognizing their EluPro™ Antibiotic-Eluting BioEnvelope technology. EluPro, launched in January 2025, is designed to protect cardiac implantable electronic devices and neurostimulators.

The product has shown strong commercial performance with 84% sequential sales growth in Q1 2025 and drove a 31% year-over-year increase in BioEnvelope sales. EluPro has secured approvals from 150 hospital value analysis committees and partnerships with seven major group purchasing organizations.

The technology addresses a significant market need, with over 600,000 CIEDs implanted annually in the U.S. and complications occurring in 5-7% of cases.

Positive

• Sales increased 84% sequentially in Q1 2025
• 31% year-over-year revenue growth in BioEnvelope sales
• Secured approvals from 150 hospital value analysis committees
• Established partnerships with 7 major group purchasing organizations
• Large addressable market with 600,000 annual CIED implants in the U.S.

Negative

• None.

Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators

SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, has been recognized with two prestigious honors—Innovation and Product Launches—in the 2025 Medical Device Network Excellence Awards. The awards celebrate Elutia’s advancements in drug eluting bioenvelopes and the successful commercial introduction of EluPro.

“We’re honored to receive recognition from Medical Device Network in both the Innovation and Product Launches categories,��� said Dr. Randy Mills, CEO of Elutia. “These awards reflect the work of two exceptional groups at Elutia: our scientists and our go-to-market team. But the truth is that neither could have succeeded in isolation. This effort is the embodiment of our CRU values, from concept to commercialization. It’s how we work here, and it’s why EluPro is successful.”

Since its pilot launch in September 2024, EluPro has demonstrated strong commercial performance, with sales increasing 84% sequentially in the first quarter of 2025 and driving a 31% year-over-year revenue increase in BioEnvelope sales. The product has received approvals from 150 hospital value analysis committees and established partnerships with seven major group purchasing organizations, reflecting widespread clinical demand and acceptance within the healthcare procurement ecosystem.

Commercially launched in January 2025, EluPro is cleared for use across all major cardiac implanted electronic device (CIED) products including pacemakers and implantable defibrillators, as well as for neurostimulation devices. Unlike synthetic alternatives, EluPro combines a soft, regenerative biomatrix with the antibiotics rifampin and minocycline to address CIED complications and support healthy healing. With more than 600,000 CIEDs implanted annually in the U.S. and complications—such as infection, migration, and skin erosion—occurring in up to 5-7% of cases, the need for improved outcomes is clear. EluPro provides a comprehensive solution for both patients and clinicians.

To learn more, visit www.elutia.com/products/elupro/.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

About the Medical Device Network Excellence Awards
The Medical Device Network Excellence Awards is an independent recognition program powered by GlobalData, analyzing over 1 billion datasets annually to recognize and rank top-tier companies and their achievements in more than 200 countries. The program honors forward-thinking, innovative companies that drive positive change across the medical device industry.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Forward-looking statements contained in this press release include, without limitation, any statements we make regarding the future success of EluPro and its future impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: the risk that clinical research data may not match preclinical study data; our ability to successfully commercialize, market and sell our EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; our ability to prevail in lawsuits and claims seeking indemnity, contribution and insurance coverage for FiberCel and other viable bone matrix product liabilities; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia’s other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c874d8cb-6241-4156-928b-1796debf88b1

This press release was published by a CLEAR® Verified individual.

FAQ

What awards did Elutia (ELUT) win at the 2025 Medical Device Network Excellence Awards?

Elutia won dual honors in the Innovation and Product Launches categories for their EluPro™ Antibiotic-Eluting BioEnvelope technology.

How has Elutia's (ELUT) EluPro performed commercially since its launch?

EluPro has shown strong performance with 84% sequential sales growth in Q1 2025 and drove a 31% year-over-year increase in BioEnvelope sales.

What is the market size for Elutia's (ELUT) EluPro product?

The U.S. market includes over 600,000 CIED implants annually, with complications occurring in 5-7% of cases.

What institutional acceptance has Elutia's (ELUT) EluPro achieved?

EluPro has received approvals from 150 hospital value analysis committees and established partnerships with seven major group purchasing organizations.

What medical devices is Elutia's (ELUT) EluPro approved for?

EluPro is cleared for use with all major cardiac implanted electronic devices (CIEDs) including pacemakers and implantable defibrillators, as well as neurostimulation devices.